NEW YORK, August 23, 2018 – The global NASH market is projected to reach $21.5 billion by 2025, with NASH being the leading cause of liver transplantation in the US in the coming years. 1 The NASH Network (NASHNET), in collaboration with The Kinetix Group, has launched a Real World Evidence study to optimize care delivery for patients with Non-Alcoholic Steatohepatitis (NASH). This initiative is in partnership with Echosens, the innovators and marketers of the FibroScan® family of products.
Tag: Networks of Excellence
The Nonalcoholic Steatohepatitis (NASH) Network in Collaboration with The Kinetix Group Participates in the International Liver Congress 2018
NEW YORK, April 6, 2018 – The NASH Network (NASHNET), in collaboration with The Kinetix Group is focused on improving NASH care delivery by collaboration on innovation, best practice sharing, and real world research. NASHNET will be participating at the upcoming International Liver Congress, hosted by the European Association for the Study of the Liver (EASL) on April 11th – 15th at Paris Expo Porte de Versailles in Paris, France.
The Kinetix Group (TKG) establishes NASH Centers of Excellence Network to Improve Care Delivery and Achieve the Quadruple Aim
NEW YORK, November 29, 2017 – Nonalcoholic Steatohepatitis (NASH) has been identified as a challenging high volume chronic disease without a standardized care delivery model. A national NASH Centers of Excellence Network (NCEN) has been designed to build best practices necessary for NASH care delivery design. The Kinetix Group’s Care Delivery Division provides the operational and strategic support for the NCEN. The initial members of the NCEN include Geisinger Health System, Ochsner Medical Center, Mount Sinai Hospital, Cedars-Sinai Health System, and Baylor Medical College, with a commitment to improve NASH care delivery.